PTC Therapeutics (PTCT) shares soared 9.7% in the last trading session to close at $36.52. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.3% loss over the past four weeks. This rise in share price is attributable to the company’s progress with its pipeline development. Last week, management reported encouraging interim data from the mid-stage PIVOT-HD study evaluating PTC518, its investigational treatment for Huntington's dis ...